RESEARCH PEPTIDE FUNDAMENTALS / COLOPHON
About This Research File
An independent, citation-anchored look at four unrelated peptides that get marketed under one shared label. Not a vendor. Not a clinic. Not medical advice.
What Peptide Scienes is
Peptide Scienes is an independent research file covering four peptides — CJC-1295, GHK-Cu, semaglutide, and tesamorelin — chosen specifically because they get discussed under one loose umbrella term, "research peptides," despite belonging to at least three unrelated pharmacological families. The organizing question behind the site is a reporter's question, not a marketing one: what does the actual published evidence say about each of these compounds, and how confidently does it say it?
The answer, it turns out, varies enormously by compound. GHK-Cu leads this desk because its file demonstrates that gap most clearly — deep cell-biology and gene-expression evidence next to a comparatively thin human-trial record outside topical skincare. Semaglutide sits at the opposite extreme, with a clinical-trial program spanning tens of thousands of participants. CJC-1295 and tesamorelin share a receptor and a hormone family but arrived at opposite regulatory fates — one a discontinued research chemical, the other an FDA-approved drug for one specific condition. Reading all four side by side, on the comparison page, is the fastest way to see how differently "evidence" can be distributed across compounds that share a marketing category.
How this file is reported
Three practices govern what appears on this site. First, every research claim traces to a specific citation — peer-reviewed journal articles, clinical-trial publications, regulatory monographs, and reviews, collected with DOIs and PubMed links on the references page. Second, findings are described at the strength they actually have: a Phase 2 finding is labeled as Phase 2, a rodent or cell-culture result is labeled as such, and an FDA-reviewed trial in one narrow patient population is not generalized beyond that population. Where a compound's file has a documented gap — no long-term safety trial, no head-to-head comparison, no data outside one indication — this file says so directly rather than filling the silence with confidence the evidence does not support.
Third, the four compound pages are cross-linked deliberately, because the same underlying questions recur across all of them: what receptor or pathway is actually engaged, how deep is the human evidence, and what happens once a compound leaves the lab and enters community use. A single shared references list aggregates every source cited across all four pages, so no citation appears twice under two different descriptions.
What it is not
Peptide Scienes is not a pharmacy, clinic, telehealth service, or vendor of any kind. It does not sell, source, or broker CJC-1295, GHK-Cu, semaglutide, tesamorelin, or anything else, and it has no referral or affiliate relationship with any supplier, pharmaceutical company, or telehealth provider. It does not diagnose, prescribe, or recommend a dose, schedule, or route of administration for any person.
Semaglutide and tesamorelin are prescription medicines available only through licensed medical providers. CJC-1295 and GHK-Cu, for any use beyond topical cosmetics, are not approved for human use by any regulatory body. Readers looking for clinical guidance should consult a licensed healthcare provider in their own jurisdiction. Editorial correspondence — citation corrections, newly published studies, out-of-date regulatory information — can be directed to the contact page; this file cannot respond to requests for medical advice.